trial

Efficacy of Bifeprunox in Patients With Schizophrenia

NCTId NCT00658645
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Terminated
Enrollment 227 (actual)
Sponsored by H. Lundbeck A/S
Primary completion 2009-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Terminated
Enrollment
227 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2008-03
Primary completion
2009-08
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
BifeprunoxQuetiapine

Sponsors

H. Lundbeck A/SLead Sponsor

Sites

38 total
Radnevo, BulgariaRadnevo, BulgariaBeijing, ChinaBeijing, ChinaMarousi, GreeceTripoli, GreeceBrasov, RomaniaBucharest, RomaniaBucharest, RomaniaBucharest, RomaniaBucharest, RomaniaIași, Romania

Linked catalysts

1
Efficacy of Bifeprunox in Patients With Schizophrenia — primary completion2009-08

Facts & assertions

4 sourced
Enrollment
227
Phase
PHASE3
Primary Completion Date
2009-08
Status
TERMINATED
relationships
The graph out of here
drug
Bifeprunox
drug
Quetiapine
drug
lead_sponsor
H. Lundbeck A/S
company
indication
Schizophrenia
indication
Schizophrenia
indication